CJC 1295 Peptide No DAC 10mg – Protide Health USA

CJC 1295 Peptide Overview & Technical Specifications

CJC 1295 peptide No DAC is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone, commonly described in the research marketplace as Modified GRF(1-29) or Mod GRF 1-29.

The Protide Health product contains:

CJC-1295 No DAC 10mg

supplied as 99% purity, HPLC-MS verified, third-party tested lyophilized research material in a 3mL vial.

Unlike the classic long-acting CJC-1295 molecule incorporating a Drug Affinity Complex, this product is specified as the No DAC form.

Its intended research identity is the modified 29-residue peptide:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Technical Specifications

• Product Name: CJC-1295 No DAC
• Alternative Names: CJC 1295 No DAC, Modified GRF(1-29), Mod GRF 1-29
• Quantity: 10mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Peptide Type: Synthetic GHRH analogue
• Peptide Length: 29 amino acids
• Molecular Formula: C152H252N44O42
• Molecular Weight: approximately 3367.90 g/mol
• PubChem CID: 91976842
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: GHRH-receptor, pituitary-signaling, endocrine, biochemical, analytical, and qualified preclinical research only

Researchers can review the supplied CJC-1295 No DAC chemical structure.

CJC 1295 Peptide Molecular Identity

The supplied CJC 1295 peptide identity aligns with PubChem CID 91976842 for the record titled “CJC1295 Without DAC.”

PubChem reports:

• Molecular Formula: C152H252N44O42
• Molecular Weight: 3367.9 g/mol
• PubChem CID: 91976842

The database record also represents a 29-residue amidated peptide.

However, the public PubChem synonym section currently contains conflicting depositor labels that include both “CJC1295 Without DAC” and “CJC1295 With DAC.”

For this reason, chemical identity should be established primarily from:

• Peptide sequence
• Molecular mass
• HPLC-MS data
• Product-specific analytical documentation

rather than relying on a product name or CAS number alone.

CAS Number Clarification

The supplied CAS number is:

863288-34-0

Because public CJC-1295 databases contain overlapping or inconsistent labeling between DAC and No-DAC forms, Protide Health should avoid representing this CAS number as uniquely definitive for Modified GRF(1-29) unless supported by the lot-specific certificate of analysis.

The page can retain the supplied number in internal documentation, but sequence and analytical verification are more reliable for distinguishing the No-DAC product.

What Is CJC 1295 Peptide?

A CJC 1295 peptide is generally discussed as a synthetic analogue of growth hormone-releasing hormone.

GHRH is an endogenous hypothalamic peptide that binds the GHRH receptor on pituitary somatotroph cells.

That receptor system is involved in regulation of:

• Growth hormone synthesis
• Growth hormone secretion
• cAMP signaling
• Pituitary endocrine responses
• GH/IGF-1-axis physiology

The No-DAC version specified here is commonly grouped with Modified GRF(1-29) research.

It should not automatically be treated as chemically or pharmacokinetically identical to long-acting CJC-1295 with DAC.

CJC 1295 Peptide & GHRH Receptor Research

The main mechanistic research context for CJC 1295 peptide No DAC is the growth hormone-releasing hormone receptor.

GHRHR is a class B G protein-coupled receptor.

Receptor activation is associated with:

• Gs-protein signaling
• Adenylate cyclase activation
• Increased cyclic AMP
• Protein kinase A signaling
• Pituitary somatotroph activity
• Growth hormone release

These pathways make Modified GRF(1-29) useful as a laboratory tool for investigating GHRH-receptor pharmacology.

Modified GRF(1-29) Research Context

Native GHRH has a longer sequence, but much of its biological receptor activity resides in its N-terminal region.

Modified GRF(1-29) uses a 29-residue backbone with amino-acid modifications intended to improve resistance to rapid enzymatic degradation.

The Protide Health CJC 1295 peptide therefore belongs to a broader family of synthetic GHRH analogues studied for:

• Receptor activation
• Peptide stability
• Proteolytic resistance
• Pituitary signaling
• Secretagogue pharmacology

CJC 1295 No DAC vs Native GHRH

Native GHRH and CJC-1295 No DAC are not chemically identical.

Native GHRH

Endogenous hypothalamic peptide involved in physiological GH release.

CJC-1295 No DAC / Modified GRF(1-29)

Synthetic shortened GHRH analogue incorporating sequence modifications intended to alter peptide stability.

This distinction matters when comparing:

• Molecular mass
• Proteolytic stability
• Pharmacokinetic behavior
• Experimental exposure
• Receptor-response studies

CJC 1295 DAC vs No DAC

The keyword cjc 1295 dac often causes confusion because the CJC-1295 name has been applied to more than one related molecule.

CJC 1295 With DAC

The classic long-acting CJC-1295 studied in human trials contains a Drug Affinity Complex, or DAC.

The DAC functionality enables covalent interaction with circulating albumin.

This produces prolonged systemic exposure.

CJC 1295 No DAC

The No-DAC material does not incorporate the albumin-binding Drug Affinity Complex.

The product on this page is specifically intended to represent:

Modified GRF(1-29) / CJC-1295 No DAC

The two compounds should not be considered interchangeable.

CJC 1295 With DAC Research

The search phrase cjc 1295 with dac usually refers to the long-acting compound evaluated in published human studies.

In a randomized controlled study of healthy adults, long-acting DAC-containing CJC-1295 produced sustained changes in GH and IGF-1 measurements over several days.

The investigators estimated a half-life of approximately 5.8–8.1 days for that long-acting formulation.

Those findings specifically concerned a molecule designed for prolonged albumin binding.

They should not be directly assigned to the CJC 1295 peptide No DAC sold by Protide Health.

Why DAC Changes the Research Profile

Albumin association can substantially influence:

• Circulating residence time
• Clearance
• Proteolytic exposure
• Pharmacokinetics
• Duration of receptor stimulation

This is why the presence or absence of DAC is not a minor naming difference.

It changes the experimental molecule’s behavior.

Researchers reviewing CJC literature should confirm which molecular form was actually studied before using a paper to support a laboratory hypothesis.

CJC 1295 Peptide & GH/IGF-1 Research

The broader CJC-1295 and GHRH analogue literature has examined the GH/IGF-1 axis.

Growth hormone can influence hepatic and peripheral production of insulin-like growth factor 1.

Experimental endpoints commonly include:

• GH concentration
• GH pulse characteristics
• IGF-1
• GHRHR activation
• Pituitary signaling

However, much of the direct human CJC-1295 literature involves the long-acting DAC form rather than Modified GRF(1-29).

For this reason, those human findings should be considered mechanistic background rather than direct clinical evidence for this No-DAC material.

CJC 1295 Peptide & GH Pulsatility

A 2006 human study investigated the long-acting DAC-containing CJC-1295 molecule and found that GH pulsatility was preserved while mean and trough GH concentrations increased.

The study involved a compound explicitly described as binding endogenous albumin and having a half-life of about eight days.

This provides useful evidence about GHRH-receptor stimulation but should not be interpreted as direct pharmacokinetic evidence for CJC 1295 peptide No DAC.

CJC 1295 Dosage Search Context

The phrase cjc 1295 dosage generally concerns human administration.

Protide Health does not provide human dosing instructions.

The 10mg quantity listed on this product page identifies the total amount of research material contained in the vial.

It is not a recommended dose.

No instructions are provided for:

• Human injection
• Daily administration
• Weekly administration
• Titration
• Body-weight calculations
• Treatment cycles
• Hormone optimization
• Reconstitution for human administration

Clinical research protocols involving DAC-containing CJC-1295 must not be converted into administration guidance for CJC-1295 No DAC.

CJC 1295 Side Effects Search Context

The phrase cjc 1295 side effects reflects consumer interest in human safety.

Human safety observations exist for the long-acting DAC-containing CJC-1295 used in controlled trials.

Those results cannot establish the safety of:

• Modified GRF(1-29)
• Independently supplied research material
• Different formulations
• Different manufacturing processes
• Different exposure patterns

A complete human safety profile for the Protide Health CJC 1295 peptide research material has not been established.

Protide Health therefore makes no claim that it is safe for human administration.

CJC 1295 for Muscle Growth Search Context

The phrase cjc 1295 for muscle growth reflects human performance and bodybuilding intent.

Research into GHRH-receptor activation and the GH/IGF-1 axis does not establish that Protide Health CJC-1295 No DAC:

• Builds muscle in humans
• Improves athletic performance
• Accelerates recovery
• Increases strength
• Changes body composition

Published endocrine findings should not be converted into bodybuilding claims.

This product is supplied exclusively as laboratory research material.

CJC 1295 No DAC Research Context

The phrase cjc 1295 no dac is the most specific terminology for this product.

In laboratory settings, potential research areas include:

• GHRH-receptor activation
• Pituitary signaling
• Cyclic-AMP pathways
• Peptide stability
• Secretagogue pharmacology
• Comparative GHRH analogue research
• Proteolytic degradation
• Analytical peptide characterization

Researchers should specify “No DAC” when distinguishing this material from the long-acting albumin-binding CJC-1295 analogue.

CJC 1295 Peptide vs Sermorelin Research Concept

Both Modified GRF(1-29) and sermorelin are related to GHRH biology.

However, they differ in sequence and chemical modifications.

Sermorelin represents the naturally occurring GHRH(1-29) sequence, whereas Modified GRF(1-29) contains substitutions intended to alter stability.

Therefore:

• They are not chemically identical.
• Analytical masses differ.
• Stability can differ.
• Experimental exposures may differ.

Results should not automatically be transferred between them.

CJC 1295 Peptide Analytical Research

HPLC-MS is especially useful for distinguishing closely related GHRH analogues.

Analytical characterization may examine:

• Retention time
• Molecular mass
• Charge-state distribution
• Sequence-derived fragments
• Purity
• Degradation products

Modern anti-doping analytical literature has also developed LC-MS/MS methods capable of distinguishing synthetic GHRH analogues and their metabolites.

This highlights the importance of analytical identity rather than relying solely on commercial naming conventions.

Research Applications

Qualified laboratories may investigate CJC 1295 peptide in research involving:

• GHRH receptor pharmacology
• Pituitary-cell signaling
• Gs/cAMP pathways
• Modified GHRH analogues
• Peptide stability
• Protease resistance
• Comparative secretagogue research
• GH-axis experimental models
• Analytical peptide identification
• In-vitro receptor research

The specific concentration and exposure conditions should be determined by validated experimental design.

Related Protide Health Research Products

Researchers comparing other endocrine or signaling peptides may review AOD-9604 for a chemically and mechanistically distinct growth-hormone-fragment research model.

The ARA-290 16mg research peptide provides a separate receptor-signaling peptide system unrelated to GHRH.

Researchers working with laboratory peptide preparations may also review bacteriostatic water with 0.9% benzyl alcoholas a separate laboratory product.

These products should not be considered mechanistically equivalent to CJC 1295 peptide No DAC.

Research Format & Storage

Protide Health supplies CJC 1295 peptide as:

• Quantity: 10mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified
• Verification: Third-party tested
• Appearance: White to off-white
• Solubility: Soluble in water

Storage specifications:

• Store at ≤6°C
• Keep sealed
• Protect from heat
• Protect from direct light
• Protect from moisture

These specifications describe laboratory storage characteristics only.

Research Limitations

Several limitations should be considered when interpreting CJC 1295 peptide research:

• CJC-1295 naming is inconsistent across public databases.
• DAC and No-DAC forms are chemically distinct.
• PubChem CID 91976842 currently includes contradictory depositor synonyms.
• CAS identifiers should not be relied upon alone to differentiate the molecular forms.
• The strongest direct human CJC-1295 trials involved a long-acting albumin-binding DAC compound.
• Those pharmacokinetic findings should not be assigned directly to Modified GRF(1-29).
• GHRH-receptor research does not establish muscle-growth effects.
• Human safety cannot be inferred from the vial specification.
• The 10mg quantity represents vial contents rather than a human dose.
• Protide Health CJC-1295 No DAC is not an FDA-approved pharmaceutical product.

For these reasons, sequence verification, molecular mass, HPLC-MS data, and lot-specific analytical documentation should be prioritized.

Literature & Citation Index

Prolonged Stimulation of Growth Hormone and IGF-I Secretion by CJC-1295

Year: 2006
PMID: 16352683
DOI: 10.1210/jc.2005-1536

Research Context: Long-acting DAC-containing CJC-1295, healthy adult subjects, GH, IGF-1, pharmacokinetics, and GHRH analogue research.

Important limitation: This study evaluated long-acting CJC-1295 rather than the No-DAC / Modified GRF(1-29) material on this page.

Pulsatile GH Secretion Persists During Continuous Stimulation by CJC-1295

Year: 2006
PMID: 17018654
DOI: 10.1210/jc.2006-1702

Research Context: Albumin-binding long-acting CJC-1295, GH pulsatility, IGF-1, and continuous GHRH-receptor stimulation.

Important limitation: The study explicitly describes an albumin-binding compound with an approximately eight-day half-life and therefore should not be treated as pharmacokinetic evidence for No-DAC Modified GRF(1-29).

Activation of the GH/IGF-1 Axis by CJC-1295

Year: 2009
PMID: 19386527
DOI: 10.1016/j.ghir.2009.03.001

Research Context: Long-acting CJC-1295, GH/IGF-1 signaling, serum proteomics, and biomarker research.

Again, this study used the long-acting CJC-1295 formulation and should not be interpreted as direct evidence for the No-DAC product.

Researchers can review broader CJC-1295, GHRH analogue, Modified GRF(1-29), and GH-axis research indexed by PubMed.

Frequently Asked Questions

What is CJC 1295 peptide?

CJC 1295 peptide No DAC is a synthetic 29-amino-acid GHRH analogue commonly referred to as Modified GRF(1-29).

What does CJC 1295 No DAC mean?

“No DAC” means the peptide does not contain the albumin-binding Drug Affinity Complex used in the long-acting form of CJC-1295.

What is the CJC-1295 No DAC sequence?

The supplied sequence is:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

What is the molecular formula?

The supplied molecular formula is:

C152H252N44O42

What is the molecular weight?

The molecular weight is approximately:

3367.90 g/mol

What is the PubChem CID?

The PubChem identifier is:

CID 91976842

Is the CJC 1295 DAC form the same as this product?

No. CJC 1295 DAC refers to the long-acting albumin-binding form, whereas this product is specified as No DAC / Modified GRF(1-29).

What is CJC 1295 with DAC?

CJC 1295 with DAC contains a Drug Affinity Complex designed to associate with albumin and substantially prolong exposure.

What is the CJC 1295 dosage?

Protide Health does not provide human cjc 1295 dosage instructions. The 10mg value identifies total vial contents only.

What are CJC 1295 side effects?

Clinical safety observations exist mainly for long-acting DAC-containing CJC-1295. They cannot establish the human safety profile of this No-DAC laboratory product.

Is CJC 1295 for muscle growth?

Although cjc 1295 for muscle growth is a common search phrase, Protide Health does not claim that CJC-1295 No DAC increases muscle growth or athletic performance in humans.

Is CAS 863288-34-0 definitive for CJC-1295 No DAC?

Public CJC-1295 identifier records are inconsistent. Protide Health should prioritize the verified sequence, mass, HPLC-MS data, and lot-specific documentation rather than relying on the CAS number alone.

What purity does Protide Health specify?

Protide Health specifies 99% purity, HPLC-MS verification, and third-party testing.

Is CJC 1295 peptide intended for human use?

No. CJC 1295 peptide is supplied exclusively for GHRH-receptor, endocrine-signaling, biochemical, molecular, analytical, in-vitro, and qualified preclinical research.

Laboratory Terms & Compliance

Laboratory Research Use Only

This CJC 1295 peptide No DAC product is supplied exclusively for laboratory research, GHRH-receptor investigation, pituitary-signaling studies, endocrine research, analytical testing, biochemical experimentation, molecular studies, in-vitro investigation, and qualified preclinical experimentation.

It is not intended for human or veterinary consumption, medical use, hormone treatment, bodybuilding, muscle-growth enhancement, athletic-performance enhancement, injection, diagnostic use, therapeutic use, or clinical administration.

No human dosage, injection schedule, muscle-growth protocol, hormone-optimization plan, treatment cycle, body-weight calculation, reconstitution instructions for human administration, or clinical guidance is provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use under applicable institutional, federal, state, and local requirements.

For research use only.